-
Related books
Drug Therapy in Dermatology (Basic and Clinical Dermatology)
by Larry E. Millikan (Hardcover - Jul 15, 2000)
Excerpt:
... "Skin aging, actinic keratoses retinol (T) 0.4-1.6% solution Skin aging Tamibarotene (Am-80) (T) 0." ...
More about this bookBioactive Natural Products: Detection, Isolation, and Structural Determination, Second Edition
by Steven M. Colegate and Russell J. Molyneux (Hardcover - Dec 14, 2007)
Excerpt:
... "2004 bexarotene S*/NM 2000 pemetrexed S*/NM 2004 raltitrexed S*/NM 1996 Tamibarotene S*/NM 2005" ...
More about this bookStrategies for Organic Drug Synthesis and Design
by Dr Daniel Lednicer (Hardcover - Oct 27, 2008)
Excerpt:
... "chain is replaced by an amide linkage. The tetralin-based compound tamibarotene (15-7) has been tested as an agent for treating leukemias." ...
More about this bookAnnual Reports in Medicinal Chemistry, Volume V44
by John E. Macor (Paperback - Nov 9, 2009)
Excerpt:
... "311 tamibarotene anticancer 2005 41, 467 tamsulosin HCl antiprostatic hypertrophy 1993 29," ...
More about this bookInnovative Leukemia and Lymphoma Therapy (Basic and Clinical Oncology)
by Gertjan J.L. Kaspers, Bertrand Coiffier, Michael C. Heinrich, and Elihu H. Estey (Hardcover - May 22, 2008)
Excerpt:
... "200 Gidron and Tallman tamibarotene (AM80), which has a low affinity for the cellular RA-binding" ...
More about this bookAnnual Reports in Medicinal Chemistry, Volume 41
by Anthony Wood (Paperback - Dec 22, 2006)
Excerpt:
... "(Parkinson's disease) [79-87] 464 20. Sorafenib (anticancer) [88-92] 466 21. Tamibarotene (anticancer) [93-96] 467 22." ...
More about this bookNational Cancer Institute Cancer Drug Dictionary
by National Cancer Institute U.S. National Institutes Of Health (Paperback - Nov 20, 2008)
Excerpt:
... "Talvesta (Other name for: talotrexin ammonium) Tamibarotene An orally active, synthetic retinoid, developed to overcome all-trans retinoic" ...
More about this bookProtein Misfolding in Neurodegenerative Diseases: Mechanisms and Therapeutic Strategies (Enzyme Inhibitors Series)
by Robert D. E. Sewell (Hardcover - Dec 3, 2007)
Excerpt:
... "the unstable polyene chain with aromatic rings (TTNPB) and heteroatoms (Tamibarotene, Am80) has resulted in potent and chemically stable RAR-selective agonists" ...
More about this bookProtein Targeting with Small Molecules: Chemical Biology Techniques and Applications
by Hiroyuki Osada (Hardcover - Aug 17, 2009)
Excerpt:
... "structural mimics of ATRA (1). A typical example is Am80 (tamibarotene: 2) (Fig. 8-1) [48,12,15]. Another potent synthetic retinoid is TAC101" ...
More about this bookGene Family Targeted Molecular Design
by Karen Lackey (Hardcover - Dec 10, 2008)
Excerpt:
... "and then Am80 (Tamibarotene) was approved as the drug for refractory and relapsed APL" ...
More about this bookPlunkett's Biotech & Genetics Industry Almanac 2010: Biotech & Genetics Industry Market Research, Statistics, Trends & Leading Companies
by Jack W. Plunkett (Paperback - Sep 9, 2009)
Excerpt:
... "TYPES OF BUSINESS: Pharmaceutical Research & Development Small-Molecule Drugs BRANDS/DIVISIONS/AFFILIATES: Tamibarotene lroxanadine INNO-206 INNO-406 Arimoclomol CONTACTS: Note: Officers with more than" ...
More about this bookThe Organic Chemistry of Drug Synthesis (Organic Chemistry Series of Drug Synthesis) (Volume 7)
by Dr Daniel Lednicer (Hardcover - Oct 31, 2007)
More about this book
medicine: tamibarotene
tamibarotene description
Tamibarotene, also called retinobenzoic acid, is orally active, synthetic retinoid, developed to overcome all-trans retinoic acid (ATRA) resistance, with potential antineoplastic activity.
Further reading
"Tamibarotene: AM 80, retinobenzoic acid, Tamibaro". Drugs in R&D (6): 359-62. 2004. PMID 15563242.This medical article is a stub. You can help Wikipedia by expanding it.v • d • eRetrieved from "http:en.boinc.org/boinc/Tamibarotene"Categories: Medicine stubs | Retinoids | Antineoplastic drugs
Tags
Keywords related to tamibarotene
travatan octriptyline amrinone fortamet azepindole cefonicid cinanserin ipodate sodium etonogestrel pharmacia 26 upjohn company iofendylate homidium bromide bromhexine inversine rescula terizidone oxymetholone mofezolac ethisterone lurosetron meticorten cyclophosphamide piperidolate difetarsone accure thioacetazone thenyldiamine amcinonide anhydron eribulin halflytely milrinone etazolate fareston romazicon aerosporin dextropropoxyphene ribasphere simvastatin tolonium chloride minaxolone mandol definity rimantadine tris alimemazine hydroflumethiazide leucocyanidin actron trileptal citicoline norvir cyamemazine nydrazid vospire avandia
-
Related news
CytRx Corporation Completes Acquisition of Innovive Pharmaceuticals,
"In the short-term, we expect tamibarotene and our pipeline of drugs in The efficacy of orally-administered tamibarotene was demonstrated in two Phase 2 ...
Read full articleCytRx Announces Publication of Paper Stating that Chaperone
The CytRx drug development pipeline includes programs in clinical development for cancer indications, including tamibarotene in a potential registration ...
Read full articleCytRx's Tamibarotene Receives Positive Opinion from the Committee for
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, ...
Read full articleCareFirst and WellDoc Communications Sponsor Diabetes Clinical Trial
Article: Clinical Trial Combining Tamibarotene with Trisenox Wireless News; September 18, 2009 ; 700+ words Wireless News 09-18-2009 Clinical Trial ...
Read full articleCytRx Unveils Clinical Development Plan for Pipeline Assets
We believe tamibarotene has strong potential as a revenue generator with a Our view is based on the substantial clinical history of tamibarotene as an ...
Read full articleCytRx Secures Key European Patent for Arimoclomol
The CytRx drug development pipeline includes programs in clinical development for cancer indications, including tamibarotene in a registration study for the ...
Read full articleCytRx to Present at the OneMedForum 2010 Conference
The CytRx drug development pipeline includes programs in clinical development for cancer indications, including tamibarotene in a registration clinical ...
Read full articleCytRx leukemia drug gets positive opinion from EMEA
O) said a panel of the European Medicines Agency (EMEA) has recommended an orphan drug status for tamibarotene, its experimental bone marrow cancer ...
Read full articleCompany Profile Report
Bafetinib/INNO-406 (Tyrosine Kinase Inhibitor); Tamibarotene (Synthetic Retinoid); INNO-206 (Doxorubicin Prodrug); INNO-305 (Cancer Vaccine) ...
Read full articlePress Release: SunPower Corporation (NASDAQ:SPWRA) is the Highest
Today (July 24, 2009), CytRx Corporation announced that its drug candidate tamibarotene has received official notification from the Committee for Orphan ...
Read full articleClinical Trial Combining Tamibarotene with Trisenox to Begin
Clinical Trial Combining Tamibarotene with Trisenox to Begin find Wireless News articles. Wireless News 09-18-2009 Clinical Trial Combining Tamibarotene ...
Read full articleArdea Biosciences Begins Phase 2b Clinical Trial of RDEA594 Article
Article: Clinical Trial Combining Tamibarotene with Trisenox Wireless News; September 18, 2009 ; 700+ words Wireless News 09-18-2009 Clinical Trial ...
Read full articleCytRx Announces $20 Million Registered Direct Offering
With the completion of this financing, we are positioned to aggressively pursue our goals of moving tamibarotene and INNO-206 toward commercialization, ...
Read full articleCytRx Reports Progress Update for Its Pivotal Phase 2 Clinical Trial
CytRx holds the North American and European rights to tamibarotene, a rationally In addition, CytRx expects tamibarotene to be granted European orphan ...
Read full articleCytRx Corporation Signs Definitive Agreement to Acquire Innovive
Tamibarotene is presently in a pivotal Phase 2 clinical trial in APL, and CytRx anticipates In April 2005, tamibarotene was approved in Japan for use in ...
Read full articleAnnounces Positive Phase 2 Results For Tamibarotene in the
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company, today announced favorable preliminary results from its Phase 2 STAR-1 registration clinical ...
Read full articleCytRx to Discuss Recent Progress at the Lippert/Heilshorn & Associates
The CytRx drug development pipeline includes programs in clinical development for cancer indications, including tamibarotene in a clinical trial for the ...
Read full articlePress Release: QualityStocks News - CytRx Corp. (CYTR) Awarded
CytRx Corp. announced that tamibarotene received an official positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European ...
Read full articleCytRx rises on analyst's 'Outperform' rating
Until then, he said a leukemia drug candidate called tamibarotene could aid CytRx's CytRx is currently conducting midstage tests of tamibarotene. ...
Read full articleProteolix to Present Carfilzomib Clinical Data at the 2009 ASCO
Wireless News; July 3, 2009 ; 700+ words of tamibarotene in other fields Tamibarotene significant anti-tumor activity in an animal trial for ...
Read full articleCytRx Expands Management Team and Broadens Oncology Franchise
The CytRx drug development pipeline includes programs in clinical development for cancer indications, including tamibarotene in a clinical trial for the ...
Read full articlePress Release: "Stocks that Standout" picks for today are: CYTR,
The primary endpoint of the open-label, non-randomized STAR-1 trial is to determine the rate of durable complete response for tamibarotene therapy when ...
Read full articleMMRC Multiple Myeloma Genomics Initiative Sequences Complete
Wireless News; July 3, 2009 ; 700+ words of tamibarotene in other fields Tamibarotene significant anti-tumor activity in an animal trial for ...
Read full articleFrost & Sullivan: E-clinical Trial Solutions Markets Show Potential
Article: Clinical Trial Combining Tamibarotene with Trisenox Wireless News; September 18, 2009 ; 700+ words Wireless News 09-18-2009 Clinical Trial ...
Read full articleCytrx Corp (CYTR.W) Company Profile Stocks Reuters.com
Tamibarotene is a synthetic retinoid designed to overcome resistance and avoid toxic side Tamibarotene was developed to overcome resistance to ATRA. ...
Read full articleNew 52 Week High Breakout Alerts Baidu, Inc. (NasdaqGS: BIDU)
CytRx Corporation (CYTR) aid a panel of the European Medicines Agency (EMEA) has recommended an orphan drug status for tamibarotene, its experimental bone ...
Read full articleCytRx Fortifies Executive Suite with Addition of Chief Medical Officer
"I am looking forward to using my skills to advance the development of several potentially important oncology drug candidates, such as tamibarotene as a ...
Read full articleCytRx to Acquire Innovive Pharmaceuticals
Tamibarotene is presently in a pivotal Phase II clinical trial in APL, and CytRx anticipates that the acquisition will accelerate the time to its first ...
Read full articleProminent Oncologist David R. Parkinson, MD, Joins CytRx's Clinical
The CytRx drug development pipeline includes programs in clinical development for cancer indications, including tamibarotene in a registration study for the ...
Read full articleMedegenics Introduces Preliminary Data for Clinical Trial Article
Article: Clinical Trial Combining Tamibarotene with Trisenox Wireless News; September 18, 2009 ; 700+ words Wireless News 09-18-2009 Clinical Trial ...
Read full articleArticle: pSivida Plans Clinical Trial to Assess Safety and Efficacy
Article: Clinical Trial Combining Tamibarotene with Trisenox Wireless News; September 18, 2009 ; 700+ words Wireless News 09-18-2009 Clinical Trial ...
Read full articleINNO-406 Demonstrates Positive Clinical Responses in Phase 1
The CytRx drug development pipeline includes six programs in clinical development, including tamibarotene in registration studies for the treatment of acute ...
Read full articleCytRx closes on Innovive Los Angeles Business from bizjournals
The biggest name amongst the drugs is tamibarotene, a treatment for leukemia. The drug has already been approved in Japan, and is currently being studied in ...
Read full articleUpdate for Its Pivotal Phase 2 Clinical Trial with Tamibarotene as
CytRx holds the North American and European rights to tamibarotene, a rationally In addition, CytRx expects tamibarotene to be granted European orphan ...
Read full articleCytRx Corporation Announces Second Quarter Results
Steven Kriegsman continued, "The drug candidate tamibarotene is a key asset in Based on successful development of tamibarotene, a New Drug Application ...
Read full articleStreetInsider.com - CytRx (CYTR) and Cephalon (CEPH) Oncology
CytRx Corporation (NASDAQ: CYTR) announced the initiation of a dose escalation study with its oncology drug candidate tamibarotene combined with TRISENOX ...
Read full articleCytRx and Cephalon Oncology Therapies to be Evaluated as Treatment
We hypothesize that the combination of tamibarotene and arsenic While currently focused on US approval for tamibarotene, CytRx considers Orphan Drug ...
Read full articleMemgen to Present Results of ISF35 Clinical Trial at ASCO Annual 2009
Article: Clinical Trial Combining Tamibarotene with Trisenox Wireless News; September 18, 2009 ; 700+ words Wireless News 09-18-2009 Clinical Trial ...
Read full articleCytRx Announces That FDA Lifts Clinical Hold of Arimoclomol in ALS
The CytRx drug development pipeline includes programs in clinical development for cancer indications, including tamibarotene in a registration study for the ...
Read full articleUpdate For Its Pivotal Phase 2 Trial With Tamibarotene As A Third
CytRx holds the North American and European rights to tamibarotene, a rationally In addition, CytRx expects tamibarotene to be granted European orphan ...
Read full articleCytRx shares fall on delay for Lou Gehrig's drug
Innovive's latest stage candidate is tamibarotene, in midstage development for a kind of acute myeloid leukemia, the most common type of leukemia. ...
Read full articleCytRx Reports 2009 Third Quarter Financial Results
In September, a dose escalating trial with tamibarotene in combination with arsenic trioxide injection was initiated to determine an appropriate dose for ...
Read full articlePress Release: CytRx Corporation (NASDAQ:CYTR) Xtreme picks of the
Today's news alerts include: CytRx's Tamibarotene Demonstrates Statistically Significant Anti-Tumor Activity in Animal Trial for Multiple Myeloma ...
Read full articleCytRx Announces 2009 Clinical and Development Milestones
Tamibarotene: The Company plans in the second and fourth quarters to report While currently focused on US approval for tamibarotene, CytRx considers ...
Read full articleMedidata Solutions Launches Clinical Trial Technology Partners
Article: Clinical Trial Combining Tamibarotene with Trisenox Wireless News; September 18, 2009 ; 700+ words Wireless News 09-18-2009 Clinical Trial ...
Read full articleCytRx reports positive study data on tamibarotene in animal trial for
CytRx reports positive study data on tamibarotene in animal trial for multiple myeloma. M2 EUROPHARMA-(C)1999-2009 M2 COMMUNICATIONS ...
Read full articleCytRx's Tamibarotene Demonstrates Statistically Significant Anti
LOS ANGELES - (Business Wire) CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company engaged in the development of high-value ...
Read full articleCytRx Announces Plan to Initiate a Phase 2 Clinical Trial with INNO
The CytRx drug development pipeline includes programs in clinical development for cancer indications, including tamibarotene in a clinical trial for the ...
Read full article